People still need treatments.. government continue with medical spending!. current price consider reasonable.. between 36 - 38 cents. In my opinion, medical sector will become safe heaven during this turmoil event
this company falls under strategic and security for the nation, asclong as no corrupt or mismanagmnt.. gahmen will always give support. Previous disaster due to previous govt request to stockile vaccine ..in the end, they dont buy. Ltat n bousted..may be replaced by khazanah or pnb, kwsp.
why you should buy at current price.. starting this year.. this company can produce and supply INSULIN!!.. next year current Biocon-Duopharma contract expired, and gov will have option to split at least to this company.
company value $500m, one QR already $100m !! ... some more out from pn7 soon. .. end of this week 50 cents. End of this year 60-70 cents!! .. obat list from 600 to 800 items. And vaccine+ Insuline. RM 1 company.
now everybody will scramble to get a piece of this company.. regulation plan approved, profit improving, insulin will generate lots of profits, ..TP 1.0 year end !
For pharmaceutical players, innovations like Pharmaniaga Bhd’s (KL:PHARMA) locally produced recombinant insulin, which received National Pharmaceutical Regulatory Agency (NPRA) approval in November, is set to launch in the first quarter of 2025, which reflects the sector’s evolution towards meeting chronic disease demands.
post pandemic ramai sakit teruk, gula takda cukai betapa lama, kini ramai ada kencing manis, big demand for ubat lagipun, aging society in malaysia terlalu ramai orang tua, sakit, ubat up up up
7081 PHARMA PHARMANIAGA BHD Quarterly rpt on consolidated results for the financial period ended 30/09/2024 Quarter: 3rd Quarter Financial Year End: 31/12/2024 Report Status: Unaudited Submitted By: Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period 30/09/2024 30/09/2023 30/09/2024 30/09/2023 RM '000 RM '000 RM '000 RM '000 1 Revenue 1,029,822 885,486 2,833,037 2,614,674 2 Profit/Loss Before Tax 138,485 (56,259) 180,863 (40,724) 3 Profit/(loss) attributable to ordinary equity holders of the parent 101,032 (49,339) 129,475 (44,731) 4 Net Profit/Loss For The Period 101,319 (49,047) 131,344 (43,957) 5 Basic Earnings/Loss Per Shares (sen) 7.01 (3.67) 8.98 (3.33) 6 Dividend Per Share (sen) 0.00 0.00 0.00 0.00 As At End of Current Quarter As At Preceding Financial Year End 7 Net Assets Per Share (RM) (0.1214) (0.2075) Remarks: You are advised to read the entire contents of the announcement or attachment. To read the entire contents of the announcement or attachment, please access the Bursa website at http://www.bursamalaysia.com
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
soon9913
2,820 posts
Posted by soon9913 > 2024-07-21 15:12 | Report Abuse
Don't all in, get ready some money to subscribe the right issue